BBB-penetrating biomimetic nanoparticles orchestrate STING activation and metabolic immunomodulation for potent glioma immunotherapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: interferon and immune responses · Nanoplatforms for cancer theranostics · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. Transforming the understanding of brain immunity [J]10.1126/science.abo7649 ↗
2. Modulating nano-bio interface via drug-framework hybridization to activate chemoimmunotherapy against glioma postoperative recurrence [J]10.1016/j.celbio.2025.100025 ↗
3. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders [J]10.1038/nrneurol.2017.188 ↗
4. Immunosuppressive mechanisms in glioblastoma [J]10.1093/neuonc/nov151 ↗
5. T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma [J]10.1158/1078-0432.CCR-17-1846 ↗
6. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors [J]10.1038/s41591-018-0135-2 ↗
7. An orally available non-nucleotide STING agonist with antitumor activity [J]10.1126/science.aba6098 ↗
8. A next-generation STING agonist MSA-2: From mechanism to application [J]10.1016/j.jconrel.2024.05.042 ↗
9. Modern methods for delivery of drugs across the blood-brain barrier [J]10.1016/j.addr.2011.11.010 ↗
10. STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs) [J]10.1016/j.canlet.2024.216700 ↗
11. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy [J]10.1186/s12943-020-01250-1 ↗
12. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation [J]10.1038/s41586-020-2682-1 ↗
13. Methionine consumption by cancer cells drives a progressive upregulation of PD-1 expression in CD4 T cells [J]10.1038/s41467-023-38316-9 ↗
14. Methionine deficiency facilitates antitumour immunity by altering m(6)A methylation of immune checkpoint transcripts [J]10.1136/gutjnl-2022-326928 ↗
15. Nintedanib-amplified effects of HSP47 siRNA on liver fibrosis therapy by inhibiting collagen secretion [J]
16. Cellular stress signaling activates type-I IFN response through FOXO3-regulated lamin posttranslational modification [J]10.1038/s41467-020-20839-0 ↗
17. Elevated Methionine Flux Drives Pyroptosis Evasion in Persister Cancer Cells [J]10.1158/0008-5472.CAN-22-1002 ↗
18. Combined effect of pH and temperature on the stability and antioxidant capacity of epigallocatechin gallate (EGCG) in aqueous system [J]10.1016/j.jfoodeng.2019.01.016 ↗
19. Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma [J]10.1038/s41467-022-31799-y ↗
20. Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy [J]10.1002/adma.202203958 ↗
21. Tumor-Derived Extracellular Vesicles Breach the Intact Blood–Brain Barrier via Transcytosis [J]10.1021/acsnano.9b04397 ↗
22. Biomimetic Nanocomposites Camouflaged with Hybrid Cell Membranes for Accurate Therapy of Early-Stage Glioma [J]10.1002/anie.202304419 ↗
23. Exploring and Analyzing the Systemic Delivery Barriers for Nanoparticles [J]10.1002/adfm.202308446 ↗
24. Precision design of engineered nanomaterials to guide immune systems for disease treatment [J]10.1016/j.matt.2022.03.005 ↗
25. Modulating active targeting nanoparticle design according to tumor progressions [J]10.1016/j.apsb.2024.12.016 ↗
26. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition [J]10.1074/jbc.M110.164046 ↗
27. mTORC1 pathway in DNA damage response [J]10.1016/j.bbamcr.2018.06.011 ↗
28. Multiple amino acid sensing inputs to mTORC1 [J]10.1038/cr.2015.146 ↗
29. Bidirectional transport of amino acids regulates mTOR and autophagy [J]10.1016/j.cell.2008.11.044 ↗
30. Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells [J]10.1593/neo.91360 ↗
31. Inflammation and cancer [J]10.1038/nature01322 ↗
32. Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors [J]10.1189/jlb.3A0414-210R ↗
33. The cGAS-STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications [J]10.1186/s13045-025-01691-5 ↗
34. The lactate dehydrogenase (LDH) isoenzyme spectrum enables optimally controlling T cell glycolysis and differentiation [J]10.1126/sciadv.add9554 ↗
35. The multiple roles of LDH in cancer [J]10.1038/s41571-022-00686-2 ↗
36. Liver Function Tests
37. Mice lacking triglyceride synthesis enzymes in adipose tissue are resistant to diet-induced obesity [J]10.7554/eLife.88049 ↗
38. Camouflaging Nanoparticles with Brain Metastatic Tumor Cell Membranes: A New Strategy to Traverse Blood–Brain Barrier for Imaging and Therapy of Brain Tumors [J]10.1002/adfm.201909369 ↗
39. LRP-1-mediated intracellular antibody delivery to the Central Nervous System [J]
40. Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review [J]10.3390/polym14040712 ↗
41. Optimizing Angiopep-2 Density on Polymeric Nanoparticles for Enhanced Blood–Brain Barrier Penetration and Glioblastoma Targeting: Insights From In Vitro and In Vivo Experiments [J]10.1002/adfm.202425165 ↗
42. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2 [J]10.1111/j.1471-4159.2008.05492.x ↗
43. Cancer-Cell-Biomimetic Nanoparticles for Targeted Therapy of Homotypic Tumors [J]10.1002/adma.201602173 ↗
44. Cell Membrane Perforation: Patterns, Mechanisms and Functions [J]10.1002/smll.202310605 ↗
45. Sodium alginate coating simultaneously increases the biosafety and immunotherapeutic activity of the cationic mRNA nanovaccine [J]10.1016/j.apsb.2022.08.015 ↗
46. pH-responsive cationic liposome for endosomal escape mediated drug delivery [J]10.1016/j.colsurfb.2020.110804 ↗
47. Engineered EGCG-Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy [J]
48. Targeting metalloimmunology via a nanoenabled approach to effectively treating solid tumors [J]10.1016/j.chempr.2024.03.020 ↗
49. Impaired learning and memory in mice induced by nano neodymium oxide and possible mechanisms [J]10.1002/tox.23148 ↗
50. Comprehensive Review on the Toxicology of Neodymium Oxide and Pharmaceutical Applications [J]10.1002/jat.4843 ↗